ArticleCancer research2011
Convection-enhanced delivery of topotecan into a PDGF-driven model of glioblastoma prolongs survival and ablates both tumor-initiating cells and recruited glial progenitors.
Article in Cancer research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 44 citations in OpenAlex.
- A phase II trial of oral gimatecan for recurrent glioblastoma.Journal of neuro-oncology · 2013Trial
- EndoSCell: A portable intraoperative histopathological microscopy device for enhanced glioma resection and prognosis in animal models.APL bioengineering · 2025Article
- An implantable, intracerebral osmotic pump for convection-enhanced drug delivery in glioblastoma multiforme.Frontiers in oncology · 2025Article
- Dietary restriction of cysteine and methionine sensitizes gliomas to ferroptosis and induces alterations in energetic metabolism.Nature communications · 2023Article
- H3K27-altered diffuse midline glioma: a paradigm shifting opportunity in direct delivery of targeted therapeutics.Expert opinion on therapeutic targets · 2023Review
- Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial.The Lancet. Oncology · 2022Article
- Convection-enhanced delivery for high-grade glioma.Neuro-oncology practice · 2022Review
- Real-Time Positron Emission Tomography Evaluation of Topotecan Brain Kinetics after Ultrasound-Mediated Blood-Brain Barrier Permeability.Pharmaceutics · 2021Article
- Role of Polymeric Local Drug Delivery in Multimodal Treatment of Malignant Glioma: A Review.International journal of nanomedicine · 2021Review
- Convection Enhanced Delivery of Topotecan for Gliomas: A Single-Center Experience.Pharmaceutics · 2020Review
- Validation of an effective implantable pump-infusion system for chronic convection-enhanced delivery of intracerebral topotecan in a large animal model.Journal of neurosurgery · 2020Article
- Imaging of Convective Drug Delivery in the Nervous System.Neurosurgery clinics of North America · 2017Review
- Convection-Enhanced Delivery.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Review
- Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies.Journal of neurosurgery · 2017Review
- Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo.Oncotarget · 2016Article
- Unique microenvironmental responses to PDGF stimulation in brain and spinal cord gliomas determine tumor phenotype.Journal of neuro-oncology · 2015Article
- Toxicity evaluation of prolonged convection-enhanced delivery of small-molecule kinase inhibitors in naïve rat brainstem.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2015Article
- Promising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer.Therapeutic delivery · 2015Review
- Convection-enhanced delivery for glioblastoma: targeted delivery of antitumor therapeutics.CNS oncology · 2015Review
- Convection-enhanced delivery of etoposide is effective against murine proneural glioblastoma.Neuro-oncology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
The contribution of microenvironment to tumor growth has important implications for optimizing chemotherapeutic response and understanding the biology of recurrent tumors. In this study, we tested the effects of locally administered topotecan on a rat model of glioblastoma that is induced by intracerebral injection of PDGF (platelet-derived growth factor)-IRES (internal ribosome entry site)-GFP (green fluorescent protein)-expressing retrovirus, treated the tumors by convection-enhanced delivery (CED) of topotecan (136 μmol/L) for 1, 4, or 7 days, and then characterized the effects on both the retrovirus-transformed tumor cells (GFP(+) cells) as well as the uninfected glial progenitor cells (GFP(-) cells) that are recruited to the tumor. Topotecan treatment reduced GFP(+) cells about 10-fold and recruited progenitors by about 80-fold while providing a significant survival advantage that improved with greater treatment duration. Regions of glial progenitor ablation occurred corresponding to the anatomic distribution of topotecan as predicted by MRI of a surrogate tracer. Histopathologic changes in recurrent tumors point to a decrease in recruitment, most likely due to the chemotherapeutic ablation of the recruitable progenitor pool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.